Arena Pharmaceuticals Announces New Strategic Focus and Cost Reduction Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St futures retreat as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
Arena Pharma (ARNA) Announces Cost-Reduction Program; Will Trim U.S. Headcount by 35%
October 27, 2015 4:01 PM EDTArena Pharma (NASDAQ: ARNA) announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities.
Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on:
advancing its APD334 program, including the ongoing Phase 2 clinical trial for ulcerative colitis, and potentially exploring additional indications beyond inflammatory bowel disease through small pilot studies;advancing its ralinepag (formerly known as APD811) program, including its ongoing Phase 2 clinical trial for pulmonary arterial hypertension (PAH), and potentially... More